MY146403A - F, g, h, i and k crystal forms of imatinib mesylate - Google Patents
F, g, h, i and k crystal forms of imatinib mesylateInfo
- Publication number
- MY146403A MY146403A MYPI20081624A MYPI20081624A MY146403A MY 146403 A MY146403 A MY 146403A MY PI20081624 A MYPI20081624 A MY PI20081624A MY PI20081624 A MYPI20081624 A MY PI20081624A MY 146403 A MY146403 A MY 146403A
- Authority
- MY
- Malaysia
- Prior art keywords
- crystal form
- crystal forms
- imatinib mesylate
- warm
- preparation
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title abstract 2
- 229960003685 imatinib mesylate Drugs 0.000 title 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 title 1
- 241001465754 Metazoa Species 0.000 abstract 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 2
- 238000002405 diagnostic procedure Methods 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 abstract 1
- 229940098779 methanesulfonic acid Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0524062A GB0524062D0 (en) | 2005-11-25 | 2005-11-25 | Organic compounds |
| GB0524061A GB0524061D0 (en) | 2005-11-25 | 2005-11-25 | Organic compounds |
| US74001705P | 2005-11-28 | 2005-11-28 | |
| US74001805P | 2005-11-28 | 2005-11-28 | |
| US74001605P | 2005-11-28 | 2005-11-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY146403A true MY146403A (en) | 2012-08-15 |
Family
ID=37847165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI20081624A MY146403A (en) | 2005-11-25 | 2006-11-23 | F, g, h, i and k crystal forms of imatinib mesylate |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US7893076B2 (enExample) |
| EP (3) | EP1960380A1 (enExample) |
| JP (2) | JP5844508B2 (enExample) |
| KR (4) | KR20080078804A (enExample) |
| CN (1) | CN102351842B (enExample) |
| AU (2) | AU2006316823A1 (enExample) |
| BR (1) | BRPI0618993A2 (enExample) |
| CA (3) | CA2824307C (enExample) |
| EC (1) | ECSP088473A (enExample) |
| MY (1) | MY146403A (enExample) |
| NO (1) | NO20082684L (enExample) |
| UY (1) | UY29964A1 (enExample) |
| WO (1) | WO2007059963A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY144177A (en) | 2004-02-04 | 2011-08-15 | Novartis Ag | Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide. |
| EP1960380A1 (en) * | 2005-11-25 | 2008-08-27 | Novartis AG | F,g,h,i and k crystal forms of imatinib mesylate |
| US8414918B2 (en) | 2007-09-25 | 2013-04-09 | Teva Pharmaceutical Industries Ltd. | Stable imatinib compositions |
| RU2365587C1 (ru) * | 2008-02-22 | 2009-08-27 | Закрытое Акционерное Общество "Фарм-Синтез" | Рентгеноаморфная безводная модификация 4-[(4-метил-1-пиперазинил)метил]-n-[4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]-амино]-фенил]бензамида метансульфоната и способ ее получения |
| CZ2009570A3 (cs) | 2009-08-26 | 2011-03-09 | Zentiva, K. S. | Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem |
| PL389357A1 (pl) | 2009-10-22 | 2011-04-26 | Tomasz Koźluk | Sole imatinibu z pochodnymi kwasów winowych i sposób ich wytwarzania |
| US20120309767A1 (en) | 2010-02-15 | 2012-12-06 | Sharma Ashwani | Process for the preparation of alpha form of imatinib mesylate |
| PL390611A1 (pl) | 2010-03-04 | 2011-09-12 | Tomasz Koźluk | Sposób otrzymywania polimorficznej formy alfa i nowa forma polimorficzna mesylanu imatinibu |
| WO2012090221A1 (en) | 2010-12-29 | 2012-07-05 | Cadila Healthcare Limited | Novel salts of imatinib |
| EP2604596A1 (en) * | 2011-12-16 | 2013-06-19 | Deva Holding Anonim Sirketi | Polymorphs of imatinib |
| US9221789B2 (en) | 2012-06-22 | 2015-12-29 | Basf Se | Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers |
| KR101242955B1 (ko) * | 2012-06-25 | 2013-03-12 | 제일약품주식회사 | 이마티닙 메실레이트 결정형 α의 제조 방법 |
| ES2683361T3 (es) | 2013-05-14 | 2018-09-26 | Hetero Research Foundation | Composiciones de Imatinib |
| WO2015081175A1 (en) * | 2013-11-26 | 2015-06-04 | Children's Medical Center Corporation | Expandable stent valve |
| WO2018089404A1 (en) | 2016-11-11 | 2018-05-17 | Mallinckrodt Nuclear Medicine Llc | Processes for generating germanium-68 with reduced volatiles |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW225528B (enExample) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| US20060073185A1 (en) | 2002-12-13 | 2006-04-06 | Bausch & Lomb Incorporated | Method and composition for contact lenses |
| WO2004106326A1 (en) | 2003-06-02 | 2004-12-09 | Hetero Drugs Limited | Novel polymorphs of imatinib mesylate |
| MY144177A (en) | 2004-02-04 | 2011-08-15 | Novartis Ag | Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide. |
| WO2005077933A1 (en) * | 2004-02-11 | 2005-08-25 | Natco Pharma Limited | Novel polymorphic form of imatinib mesylate and a process for its preparation |
| UA84462C2 (ru) | 2004-04-02 | 2008-10-27 | Институт Фармацевтични | Полиморфные модификации кислотно-аддитивных солей иматиниба с метансульфоновой кислотой |
| CN1976709A (zh) | 2004-06-04 | 2007-06-06 | 比奥尼斯生命科学公司 | 伊马替尼在治疗肝脏疾病和病毒感染中的用途 |
| KR101348625B1 (ko) * | 2004-09-02 | 2014-01-07 | 씨아이피엘에이 엘티디. | 이매티닙 메실레이트의 안정한 결정형 및 그의 제조방법 |
| WO2006048890A1 (en) * | 2004-11-04 | 2006-05-11 | Sun Pharmaceutical Industries Limited | Imatinib mesylate crystal form and process for preparation thereof |
| WO2006054314A1 (en) * | 2004-11-17 | 2006-05-26 | Natco Pharma Limited | Polymorphic forms of imatinib mesylate |
| US9804295B2 (en) | 2005-05-05 | 2017-10-31 | Novartis Ag | Ophthalmic devices for sustained delivery of active compounds |
| GB0511066D0 (en) | 2005-05-31 | 2005-07-06 | Novartis Ag | Organic compounds |
| MX2008002541A (es) | 2005-08-26 | 2008-03-14 | Novartis Ag | Formas de cristal delta y epsilon de mesilato de imatinib. |
| EP1960380A1 (en) * | 2005-11-25 | 2008-08-27 | Novartis AG | F,g,h,i and k crystal forms of imatinib mesylate |
-
2006
- 2006-11-23 EP EP06818763A patent/EP1960380A1/en not_active Withdrawn
- 2006-11-23 KR KR1020087012363A patent/KR20080078804A/ko not_active Ceased
- 2006-11-23 CA CA2824307A patent/CA2824307C/en not_active Expired - Fee Related
- 2006-11-23 WO PCT/EP2006/011240 patent/WO2007059963A1/en not_active Ceased
- 2006-11-23 KR KR1020137031545A patent/KR20130137721A/ko not_active Ceased
- 2006-11-23 JP JP2008541641A patent/JP5844508B2/ja not_active Expired - Fee Related
- 2006-11-23 EP EP12177119A patent/EP2546248A1/en not_active Withdrawn
- 2006-11-23 BR BRPI0618993-8A patent/BRPI0618993A2/pt not_active IP Right Cessation
- 2006-11-23 UY UY29964A patent/UY29964A1/es not_active Application Discontinuation
- 2006-11-23 EP EP12177131.5A patent/EP2578580A1/en not_active Withdrawn
- 2006-11-23 KR KR1020137031544A patent/KR20130140909A/ko not_active Ceased
- 2006-11-23 MY MYPI20081624A patent/MY146403A/en unknown
- 2006-11-23 CA CA2824301A patent/CA2824301C/en not_active Expired - Fee Related
- 2006-11-23 AU AU2006316823A patent/AU2006316823A1/en not_active Abandoned
- 2006-11-23 KR KR1020137031543A patent/KR20130141712A/ko not_active Ceased
- 2006-11-23 CA CA2628330A patent/CA2628330C/en not_active Expired - Fee Related
- 2006-11-23 CN CN201110232553.6A patent/CN102351842B/zh not_active Expired - Fee Related
- 2006-11-23 US US12/094,629 patent/US7893076B2/en not_active Expired - Fee Related
-
2008
- 2008-05-20 EC EC2008008473A patent/ECSP088473A/es unknown
- 2008-06-16 NO NO20082684A patent/NO20082684L/no not_active Application Discontinuation
-
2011
- 2011-01-14 US US13/006,505 patent/US8198289B2/en not_active Expired - Fee Related
- 2011-03-22 AU AU2011201286A patent/AU2011201286A1/en not_active Ceased
- 2011-07-15 US US13/183,557 patent/US8507515B2/en not_active Expired - Fee Related
- 2011-07-15 US US13/183,600 patent/US8846706B2/en not_active Expired - Fee Related
- 2011-07-15 US US13/183,572 patent/US8592440B2/en not_active Expired - Fee Related
-
2012
- 2012-05-15 US US13/472,000 patent/US8633213B2/en not_active Expired - Fee Related
-
2014
- 2014-01-16 JP JP2014005741A patent/JP2014074067A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY148375A (en) | Delta and epsilon crystal forms of imatinib mesylate | |
| MX2009013272A (es) | Formas amorfas estabilzadas de mesilato de imatinib. | |
| NO20082684L (no) | F-, G-, H-, I- og K-krystallformer av imatinibmesylat | |
| IL196543A (en) | Pyridazinone derivatives, pharmaceutical preparations containing them for use in the treatment of disorders | |
| PH12015502792A1 (en) | Crystalline bromodomain inhibitors | |
| GEP20084452B (en) | Sulfonamide derivatives for the treatment of diseases | |
| MX378495B (es) | Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil)pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamida. | |
| NO20076635L (no) | Krystallinske og andre former for 4-amino-5-fluor-3-[6-(4-metylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-kinolin-2-on-melkesyresalter | |
| NO20081434L (no) | 5-(fenylisoksazolyletoksy)-triazol-3-yl substituert pyridinsammensetninger for behandling av neurologisk, psykiatrisk eller smerteforstyrrelser | |
| BRPI0813625A2 (pt) | Imidazo-[1,2b]-piridozinas 2,3,7-substituídos para tratamento de doenças mediadas por alzk4 ou alk5 | |
| TW200728305A (en) | Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease | |
| NO20092639L (no) | 4-fenyl-6-(2,2,2-trifluor-1-fenyletoksy)pynmidinbaserte forbindelser og anvendelser derav | |
| IL188942A0 (en) | Benzimidazole derivatives and pharmaceutical compositions containing the same | |
| MY147677A (en) | Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases | |
| HRP20050710A2 (en) | Substituted n-arylheterocycles, method for production and use thereof as medicaments | |
| TW200633980A (en) | Pyridones useful as inhibitors of kinases | |
| ATE470443T1 (de) | Indol-1-yl-essigsäurederivate | |
| MA32717B1 (fr) | Sels de n-[6-cis- (2.6-dimethylmorpholin-4-yl)pyridin-3-yl)-2-methyl-4'- (trifluoromethoxy)- [1.1'-biphenyl]-3-carboxamide | |
| WO2006057945A3 (en) | 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease | |
| GB0524814D0 (en) | Compounds | |
| DE602007004327D1 (de) | Einen azepin-kern enthaltende antagonisten des histaminrezeptors | |
| MX2008001211A (es) | Derivados de bencilpiperazina y su uso medico. | |
| PL1853232T3 (pl) | Trwałe postaci krystaliczne mesylanu bifeprunoksu, postaci dawkowania oraz sposoby ich stosowania | |
| IL162983A (en) | Use of imatinib for the manufacture of pharmaceutical compositions for the treatment of rheumatoid arthritis | |
| MX2009011576A (es) | Nuevos derivados de 4,8-difenil-poliazanaftaleno. |